Melanoma vaccine - GlaxoSmithKline

Drug Profile

Melanoma vaccine - GlaxoSmithKline

Alternative Names: Melacine

Latest Information Update: 10 Oct 2006

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma

Most Recent Events

  • 08 Dec 2003 Melacine® is available for licensing (www.corixa.com)
  • 08 Dec 2003 Discontinued - Phase-III for Malignant melanoma in USA (IM, Injection)
  • 31 Jul 2002 Schering Plough has terminated its worldwide license for Melacine®
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top